US Patent

US12121523 — Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2029-09-04 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating attention deficit/hyperactivity disorder (ADHD) or ADHD-related disorders using a pharmaceutical agent with specific properties.

USPTO Abstract

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Drugs covered by this patent

viloxazine-hydrochloride (VILOXAZINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-727`	—	viloxazine-hydrochloride
`U-727`	—	viloxazine-hydrochloride
`U-727`	—	viloxazine-hydrochloride

Patent Metadata

Patent number: US12121523
Jurisdiction: US
Classification: Method of Use
Expires: 2029-09-04
Drug substance claim: No
Drug product claim: No
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.